PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Rössler, J. ; Pich, D. ; Krähling, V.* ; Becker, S.* ; Keppler, O.T.* ; Zeidler, R. ; Hammerschmidt, W.

SARS-CoV-2 and Epstein-Barr Virus-like particles associate and fuse with extracellular vesicles in virus neutralization tests.

Biomedicines 11:2892 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The successful development of effective viral vaccines depends on well-known correlates of protection, high immunogenicity, acceptable safety criteria, low reactogenicity, and well-designed immune monitoring and serology. Virus-neutralizing antibodies are often a good correlate of protective immunity, and their serum concentration is a key parameter during the pre-clinical and clinical testing of vaccine candidates. Viruses are inherently infectious and potentially harmful, but we and others developed replication-defective SARS-CoV-2 virus-like-particles (VLPs) as surrogates for infection to quantitate neutralizing antibodies with appropriate target cells using a split enzyme-based approach. Here, we show that SARS-CoV-2 and Epstein-Barr virus (EBV)-derived VLPs associate and fuse with extracellular vesicles in a highly specific manner, mediated by the respective viral fusion proteins and their corresponding host receptors. We highlight the capacity of virus-neutralizing antibodies to interfere with this interaction and demonstrate a potent application using this technology. To overcome the common limitations of most virus neutralization tests, we developed a quick in vitro diagnostic assay based on the fusion of SARS-CoV-2 VLPs with susceptible vesicles to quantitate neutralizing antibodies without the need for infectious viruses or living cells. We validated this method by testing a set of COVID-19 patient serum samples, correlated the results with those of a conventional test, and found good sensitivity and specificity. Furthermore, we demonstrate that this serological assay can be adapted to a human herpesvirus, EBV, and possibly other enveloped viruses.
Impact Factor
Scopus SNIP
Altmetric
4.700
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Ebv ; Epstein–barr Virus ; Sars-cov-2 ; Antibody ; Diagnostic Test ; Extracellular Vesicle ; Fusion ; Virus Neutralization Test ; Virus-like Particle; Host-cell; Entry; Protein; Antibodies; Proteases
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2227-9059
e-ISSN 2227-9059
Zeitschrift Biomedicines
Quellenangaben Band: 11, Heft: 11, Seiten: , Artikelnummer: 2892 Supplement: ,
Verlag MDPI
Verlagsort Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)
Institute of Structural Biology (STB)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
Enabling and Novel Technologies
PSP-Element(e) G-501500-001
G-503010-001
Förderungen Bundesministerium fuer Bildung und Forschung
Deutsche Krebshilfe
NIH
Deutsche Forschungsgemeinschaft
Initiative and Networking Fund of the Helmholtz Association of German Research Centres (HGF) under the CORAERO project
Free State of Bavaria under the Excellence Strategy of the Federal Government
Federal Ministry of Education and Research (BMBF)
LMUexcellent
DOI 10.3390/biomedicines11112892
WOS ID 001107803500001
Scopus ID 85178386912
PubMed ID 38001893
Erfassungsdatum 2023-12-19
[➜Korrektur melden]